Tokyo Tape
Sign in
← Kirin Holdings

Quarterly report · Q1

2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥501.8bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥450.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥30.8bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥11.0bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥44.2bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥20.1bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥25.9bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥5.6bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥32.6bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥11.3bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.00Tat 2024-03-31Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.47Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.55Tat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.46Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.23Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.16Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥971.9bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥151.2bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥116.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥39.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥41.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥65.3bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.4bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥34.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥8.6bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥31.982024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥6.92023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥31.982024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥6.92023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio38.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.4%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥20.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥4.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥15.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31−¥158m
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥12.3bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥238.6bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥238.2bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥379m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2024-01-01 → 2024-03-31¥32.7bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2024-01-01 → 2024-03-31¥31.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥726m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2024-01-01 → 2024-03-31−¥1.7bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥122.2bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥121.5bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥645m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥12.2bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥105.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥105.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥67m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥22.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥16.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31−¥265m
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥11.5bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥225.4bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥225.1bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥300m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥20.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2023-01-01 → 2023-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2023-01-01 → 2023-03-31¥17.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥991m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2023-01-01 → 2023-03-31−¥1.4bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥108.6bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥108.0bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥609m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥9.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥93.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥93.4bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥107m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥16.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 779
ItemContextValueUnit
Decrease increase in deposits for purchase of treausury shares of subsidiaries fin cf IFRSCurrentYTDDuration-7599000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-29559000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-29560000000JPY
Dividends paid to non controlling interests fin cf IFRSPrior1YTDDuration-6713000000JPY
Dividends paid to non controlling interests fin cf IFRSCurrentYTDDuration-7215000000JPY
Other fin cf IFRSPrior1YTDDuration0JPY
Other fin cf IFRSCurrentYTDDuration-72000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-8617000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration34748000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration1477000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration10523000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration3309000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration19808000000JPY
Cash and cash equivalents IFRSPrior2YearInstant88060000000JPY
Cash and cash equivalents IFRSPrior1YearInstant131399000000JPY
Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRSPrior1YTDDuration25484000000JPY
Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRSCurrentYTDDuration－JPY
Cash and cash equivalents IFRSPrior1QuarterInstant116852000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant151207000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember225140000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember108014000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember93428000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember17374000000JPY
Revenue from external customers IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember6373000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration450329000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember300000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember609000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember107000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember991000000JPY
Intersegment revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember15961000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-17968000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember225440000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember108623000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember93535000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember18365000000JPY
Revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember22335000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-17968000000JPY
Revenue IFRSPrior1YTDDuration450329000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember20922000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember9637000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember16199000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember-1415000000JPY
Segment profit loss IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-265000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-11505000000JPY
Segment profit loss IFRSPrior1YTDDuration33573000000JPY
Other operating income IFRSPrior1YTDDuration3222000000JPY
Other operating expenses IFRSPrior1YTDDuration25803000000JPY
Finance income IFRSPrior1YTDDuration1949000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass